

Regd. Office :

'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015, India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

January 20, 2017

To,
The National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra-Kurla Complex, Bandra (East)
Mumbai – 400 051

Kind Attn.: Ms. Charmi Dharod – Assistant Manager – Listing Compliance

Sub.: Clarification

Ref.: Your mail dated January 20, 2017.

Dear Madam,

In response to your mail, we would like to state that the acquisition of Sentynl Therapeutics Inc., USA [Sentynl] is not done by Cadila Healthcare Limited. The acquisition is done by Company's subsidiary in USA and therefore no government or regulatory approvals are required in India. Further, we state that the necessary disclosure by way of a press release was made just after the completion of transaction by our US subsidiary Company.

The acquisition does not fall within related party transaction and no promoter / promoter group companies have any interest in the acquired entity. Further, we inform that the US subsidiary has acquired Sentynl on cash payment.

Sentynl is a US based Pharma Company specialized in marketing of products in the pain management segment.

Thanking you,

Yours faithfully,
For, **Cadila Healthcare Limited**



Upen H. Shah
Company Secretary

